SAN FRANCISCO, CA–(Marketwired – September 01, 2016) – The late-stage biopharmaceutical company Soligenix Inc. (OTCQB: SNGX) has had a string of good news. Revenue is up, the FDA awarded orphan status to a key drug, and BARDA and NIAID have granted the firm additional funding, plus the company is developing vaccines against Ebola and ricin, and has several other ongoing trials. Analyst Grant Zeng of Zacks Investment Research assesses the landscape.
Included in this article is: Soligenix Inc.
In an Aug. 18 research report, Zacks analyst Grant Zeng reviewed Soligenix’s Q2 financials. “Total revenue for the second quarter was $3.2 million, as compared to $1.1 million for the same period for the prior year. Revenues included contracts with BARDA and NIAID in support of OrbeShield® development in the treatment of gastrointestinal acute radiation syndrome (GI AR and advanced development of the Company thermostabilization technology, ThermoVax, combined with its ricin toxin vaccine RiVax, as a medical countermeasure to prevent the effects of ricin exposure,” the analyst stated.
Continue reading this article: Soligenix’s Diversified Pipeline Advances on All Fronts
About Streetwise Reports – The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURE:
The following companies mentioned in this article are sponsors of Streetwise Reports: Soligenix Inc. The companies mentioned in this article were not involved in any aspect of the article preparation. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
Please see the end of the article for the complete disclosure: Soligenix’s Diversified Pipeline Advances on All Fronts
Jim Patrick
Email contact
